Re: Farmas USA
Buenos resultados de TGTX
• TG Therapeutics (NASDAQ:TGTX) is up 17% premarket on light volume on the heels of positive results from a Phase 2b clinical trial, UNITY-NHL, evaluating umbralisib in patients with treatment-resistant non-Hodgkin lymphoma (NHL).
• The study med the primary endpoint of overall response rate (ORR) and met the company's target guidance of 40 - 50% ORR.
• Preliminary data will be presented at AACR on April 1. Complete results will be submitted for presentation at a future medical conference (a certainty that it will be ASCO in May/June).
• Management will host a conference call this morning at 8:30 am ET to discuss the result